Suvratoxumab is under clinical development by Aridis Pharmaceuticals and currently in Phase II for Ventilator Associated Pneumonia (VAP). According to GlobalData, Phase II drugs for Ventilator Associated Pneumonia (VAP) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Suvratoxumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Suvratoxumab (MEDI-4893) is under development for the prevention of ventilator associated pneumonia caused by Staphylococcus aureus. The drug candidate is administered intravenously in the form of solution. It is a potent human Immunoglobulin G (IgG)1 monoclonal antibody that binds to an alpha toxin released by Staphylococcus aureus. It is a new molecular entity.
Aridis Pharmaceuticals overview
Aridis Pharmaceuticals (Aridis) is a biopharmaceutical company. The company develops novel, differentiated therapies for infectious diseases. Its pipeline products include AR-301 mAb, AR-105 mAb, AR-101 mAb, AR-501(Gallium Citrate), AR-401 mAb and AR-201 mAb. The company uses a disruptive platform technology to discover potent human monoclonal antibodies from patients. Its proprietary platform, MabIgXis used to discover potent therapeutic antibodies for any diseases and to generate an unrivaled product portfolio ofanti-infective mAbs. The company also works on macromolecular stabilization technology for increase the stability of vaccines. Aridis is headquartered in San Jose, California, the US
For a complete picture of Suvratoxumab’s drug-specific PTSR and LoA scores, buy the report here.